Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
thyroid eye disease
Biotech
Ethyreal Bio raises $101M, joining biotechs gunning for Tepezza
Backed by investors including Atlas Venture and Medicxi Ventures, Ethyreal has quietly advanced an anti-TSHR antibody to the cusp of the clinic.
Nick Paul Taylor
Jun 10, 2026 9:35am
Immunovant pays out $39M to call time on 1st-gen FcRn inhibitor
May 20, 2026 8:31am
Alumis pulls back from would-be rival to Amgen’s Tepezza
May 15, 2026 3:44am
Viridian’s Tepezza rival racks up another ph. 3 win
May 5, 2026 8:00am
Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials
Apr 2, 2026 7:27am
Viridian’s Tepezza rival scores ph. 3 win, but investors unsure
Mar 30, 2026 10:11am
